Indefinite Delivery Contract 75N95024D00021
Award Date 6/20/24
Last Date to Order 6/19/30
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
Not listed NAICS Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Service Contract Act
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed Similar IDVs
- This indefinite delivery contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to the Lovelace Biomedical Research Institute. The contract has a ceiling value of $48,882,666.00 and a period of performance through August 5, 2030. The purpose of this IDC is to obtain pharmacology studies, animal model development, and related services to support NCATS' Division of Preclinical Innovation drug...
- The federal contract IDV award is for safety evaluation and toxicology studies and related services to support drug development efforts of the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The prime contractor, SRI International, a nonprofit research and development institute, will provide in vitro and in vivo exploratory and Investigational New Drug (IND)-directed toxicology studies for small molecule and biologic...
- This is a multiple award indefinite delivery contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to conduct safety evaluation and toxicology studies to support drug development. The $48.6 million contract has a 6-year ordering period from June 2024 to June 2030. The contractor, IIT Research Institute (IITRI), a non-profit research organization, will perform in vitro and in vivo exploratory and...
- The National Center for Advancing Translational Sciences (NCATS), a civilian agency, has awarded an indefinite delivery contract (IDC) worth up to $48,622,546 to Charles River Laboratories, Inc. to provide safety evaluation and toxicology studies and related services to support drug development. The contract has a period of performance from August 2024 to August 2030. Under this IDC, Charles River will perform in vitro and in vivo exploratory and Investigational New Drug (IND)-directed...
- This indefinite delivery contract was awarded by the National Center for Advancing Translational Sciences (NCATS), part of the U.S. Department of Health and Human Services, to Lovelace Biomedical Research Institute, a not-for-profit contract research organization based in Albuquerque, New Mexico. The $17.89 million multiple-award contract, which runs through April 2025, is for contract research organization (CRO) support for NCATS' medicinal chemistry work focused on lead optimization. Under the...
- This Indefinite Delivery Contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services, to the prime contractor Southern Research Institute, a non-profit research organization located in Birmingham, Alabama. The IDC, with a ceiling value of $17,891,012, is to provide CRO (Contract Research Organization) support for NCATS' Medicinal Chemistry for Lead Optimization program. This includes services...
- The federal contract IDV award is for "PHARMACOLOGY STUDIES AND ANIMAL MODEL DEVELOPMENT AND RELATED SERVICES FOR DRUG DEVELOPMENT" and was issued by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH). The multiple-award, indefinite delivery contract has a ceiling value of $48,882,666.00 and a period of performance through August 5, 2030. The prime contractor is Advanced Bioscience Laboratories, Inc....
- This Indefinite Delivery Contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL). The $49.9 million, multiple-award IDC will provide Chemistry, Manufacturing, and Control (CMC) and related services to support the development of drug products from August 2024 through July 2031. The contract aims to obtain a broad range of preclinical services...
- This indefinite delivery contract (IDC) was awarded by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services, to Sri International, a non-profit research and development institute. The $9.75 million IDC has a period of performance from September 12, 2023 to September 11, 2028 and is for toxicological evaluations of potential medications to support NIDA's mission. Under this IDC, Sri International has been awarded two task orders so far....
- The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, has awarded a $48.6 million multiple-award indefinite delivery contract to conduct safety evaluation and toxicology studies in support of drug development. The contract has a 6-year ordering period and allows NCATS to issue task orders for in vitro and in vivo safety testing services, including genetic toxicology, general toxicology, and pharmacology...